187 results on '"Yegya-Raman, Nikhil"'
Search Results
2. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
3. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
4. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment
5. Breast Reconstruction Complications After Postmastectomy Proton Radiation Therapy for Breast Cancer
6. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation
7. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
8. One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia
9. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
10. Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
11. A Review of Advances in Radiotherapy in the Setting of Esophageal Cancers
12. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
13. Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer
14. Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
15. Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer
16. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases
17. Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era
18. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review
19. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
20. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
21. Plunging into the PACIFIC: Outcomes of Patients with Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation
22. The Effective Radiation Dose to Immune Cells Predicts Lymphopenia and Inferior Cancer Control in Locally Advanced NSCLC
23. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation
24. SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma
25. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
26. Statin therapy, cardiac events, and survival in patients with non-small cell lung cancer receiving definitive radiotherapy
27. One-Year Outcomes Following Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia.
28. Breast Reconstruction Complications Following Post-Mastectomy Proton Radiotherapy for Breast Cancer
29. Clinical practice and outcomes of palliative radiation therapy in pediatric oncology patients: An international comparison of experiences from two distinct countries and health care systems
30. 5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost
31. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy
32. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy
33. SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma.
34. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Use of Local Therapy in Patients with Oligoprogression
35. Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer
36. Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation
37. Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
38. Daily Image Guidance With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer
39. Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non–Small Cell Lung Cancer Are Associated With Decreases in Overall Survival
40. Prospective Feasibility and Phase I/II Trial of Preoperative Proton Beam Therapy with Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer
41. Prospective Feasibility and Phase 1/2 Trial of Preoperative Proton Beam Therapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer.
42. Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer
43. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
44. Factors Associated With Travel Distance in the Receipt of Proton Breast Radiation Therapy
45. Acute and long-term toxicity of whole pelvis proton radiation therapy for definitive or adjuvant management of gynecologic cancers.
46. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
47. Radiation Therapy in Metastatic Soft Tissue Sarcoma: From Palliation to Ablation
48. Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer
49. Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy
50. Montelukast in hospitalized patients diagnosed with COVID-19.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.